Latest Pharmx Technologies (ASX:PHX) News

Small caps stole the week, led by a big funding deal in gold and two revenue breakouts. Meanwhile, some well-known names slid after profit updates failed to calm nerves on costs and outlooks.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

One microcap exploded higher on a tiny capital raise, while several software names were sold hard despite reporting growth. The week split cleanly between “cash in the bank” stories and “still burning cash” worries.

Pharmx Technologies reported a 3.1% revenue increase to $3.89 million for H1 FY26 but posted a net loss of $512,000 driven by strategic investments. The company also announced a significant multi-year alliance with Sigma Healthcare.

Pharmx Technologies has entered a multi-year strategic alliance with Sigma Healthcare, becoming the preferred EDI provider for Sigma and Chemist Warehouse across Australia and New Zealand, while Sigma takes a significant equity stake.

Pharmx Technologies reported a 13% increase in FY25 revenues to $7.53 million, driven by strong growth across its Gateway and Marketplace platforms. The company maintained positive EBITDA and a solid cash position despite legal expenses, setting the stage for an ambitious FY26 growth strategy.

Pharmx Technologies has reported a 13% revenue increase to $7.5 million for FY25, driven by expanded partnerships and platform innovations, despite a dip in EBITDA due to heavy investment.

Pharmx Technologies Limited reported a 13% increase in revenue for FY25, driven by expanded supplier-pharmacy connections and Marketplace platform growth, while profit before tax declined due to significant investments in new technology platforms.

Pharmx Technologies has resumed trading on the ASX following the renewal of its pivotal National Diabetes Services Scheme agreement, signaling stability for the healthcare tech firm.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.